# Adiana

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adiana

- Industry: Consumer Products
- Headquarters: Redwood City, US
- Website: www.adiana.com
- Total disclosed funding: $23M
- Latest round: Series D (Aug 25, 2005)
- Investors on record: 9

## About

Adiana is a medical technology company focused on advancing women's health through innovative solutions, particularly in permanent contraception. Their proprietary Adiana System utilizes radiofrequency energy for a minimally invasive approach to contraception.Adiana, founded in 1997 and headquartered in Redwood City, US, specializes in medical technologies aimed at improving reproductive health. The company was acquired by Cytyc in March 2007 for USD 215 mn. It has completed a total of 3 transactions since its inception.Adiana's primary offering is the Adiana System, designed for permanent contraception via a non-surgical procedure using radiofrequency energy to create a small incision in the fallopian tubes. This innovative approach is aimed at women desiring reliable contraception without surgical intervention. The company distributes its products mainly across North America and select regions in Europe, working with healthcare providers and patients in need of advanced reproductive health solutions.Adiana generates revenue through direct sales to healthcare providers and partnerships with medical facilities focusing on reproductive health. Their revenue model includes B2B sales of the Adiana System to hospitals and clinics, alongside ongoing support and training services for medical professionals, ensuring long-term client relationships within the reproductive health sector.Following the acquisition by Cytyc in March 2007, Adiana plans to leverage recent funding of USD 215 mn to further develop its offerings and expand into new markets. The company is exploring the introduction of new products aimed at enhancing women's health, with specific target regions in Europe and Asia planned for expansion by 2025. The funding will support these development and expansion initiatives.

## Funding rounds

- Series D, Aug 25, 2005, $23M — Abingworth, Alloy Ventures, Delphi Ventures, Forward Ventures, OrbiMed Advisors, Tullis Health Investors, Oakwood Medical Investors, Boston Scientific Ventures, Kaiser Permanente Ventures

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D
- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series D
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series D
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series D
- Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series D
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series D